StockNews.AI
BBNX
StockNews.AI
105 days

Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025

1. BBNX reported Q1 2025 net sales of $17.6 million, a 36% increase. 2. Pharmacy Benefit Plan sales surged 360% to $3.8 million from Q1 2024. 3. Installed customer base grew to 19,151, a 291% year-over-year increase. 4. Operational loss increased to $18.6 million, compared to $9.5 million last year. 5. Annual revenue guidance raised to $82-$87 million, up from $80-$85 million.

Earnings
+26.61%Current Return
VS
+0.42%S&P 500
$11.3505/06 04:08 PM EDTEvent Start
$14.3705/07 11:01 PM EDTLatest Updated
20m saved
Insight
Article

FAQ

Why Bullish?

The increase in sales and guidance indicates strong growth potential, despite losses.

How important is it?

Strong growth rates and revised revenue guidance signal positive sentiment around BBNX's future.

Why Short Term?

Immediate market reaction likely due to updated revenue guidance and sales increases.

Related Companies

PBPXERSPMT
May 06, 2025 16:02 ET  | Source: Beta Bionics, Inc. IRVINE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended March 31, 2025 and raised its annual guidance for the year ending December 31, 2025. First Quarter 2025 Financial Results & Key Metrics Net sales of $17.6 million, up 36% compared to $12.9 million in the first quarter of 2024. Durable Medical Equipment (DME) channel net sales of $13.8 million, up 14% compared to $12.1 million in the first quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $3.8 million, up 360% compared to $0.8 million in the first quarter of 2024. Gross margin of 50.9%, down 482 basis points compared to 55.7% in the first quarter of 2024.Installed customer base (calculated as all new patient starts over a rolling four-year period) of 19,151 users, up 291% compared to 4,901 in the first quarter of 2024.3,853 new patient starts, up 48% compared to 2,597 new patient starts in the first quarter of 2024. 71% of new patient starts came from multiple daily injections (MDI).Low 20s percentage of new patient starts reimbursed through the PBP channel. Loss from operations of $18.6 million, or negative 106% of sales, compared to $9.5 million or negative 73% of sales in the first quarter of 2024.Net loss of $28.7 million, or negative 162% of sales, compared to $12.4 million or negative 96% of sales in the first quarter of 2024.Adjusted EBITDA(1) of negative $15.5 million, or negative 88% of sales, compared to negative $7.8 million or negative 60% of sales in the first quarter of 2024.$295.5 million in cash, cash equivalents, short-term investments, and long-term investments as of March 31, 2025. (1) See “Non-GAAP Financial Measures” below for additional information. A reconciliation of the non-GAAP financial measure to its most directly comparable GAAP financial measure can be found in Table E. Recent Strategic Highlights On January 31, 2025, completed upsized initial public offering and concurrent private placement, raising approximately $206.0 million in net proceeds to the company.Announced that effective February 1, 2025, Prime Therapeutics has added the iLet Bionic Pancreas and associated monthly supplies to its largest national commercial formulary. Beta Bionics is actively working with the health plans that partner with Prime Therapeutics to drive coverage of iLet under their pharmacy benefit, per Prime’s recommendation to the health plans.For plans that cover the iLet Bionic Pancreas under their pharmacy benefit, this decision significantly reduces the potentially large up-front cost of the pump for both the patient and the plan, while easing the administrative burden for the physician when prescribing the iLet Bionic Pancreas. Initiated enrollment in March for the glucagon pharmacokinetic-pharmacodynamic bridging trial in Canada. The trial is intended to enable Beta Bionics to bridge previous bihormonal clinical data, which tested prior formulations of glucagon in three pre-pivotal inpatient and six pre-pivotal outpatient clinical trials, to Beta Bionics’ glucagon candidate developed by Xeris Pharmaceuticals for use in the bihormonal configuration of the iLet. Announced an investor event on June 22, 2025, to be hosted in conjunction with the 85th Scientific Sessions of the American Diabetes Association. Agenda to include updates on commercial and financial performance, a demonstration of the patch pump in development, a review of the adaptive closed-loop algorithm, and new real-world data. 2025 Full Year Guidance Estimated total revenue of approximately $82 million to $87 million (previously $80 million to $85 million).Estimated 22% to 25% of new patient starts reimbursed through the PBP channel (previously greater than 20%).Estimated gross margin of 50% to 53% (previously at least 50%). Webcast & Conference Call Details Beta Bionics will host a conference call and concurrent webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s first quarter 2025 performance. The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. You may also access the live call by dialing (888) 596-4144, passcode is 8363701. Non-GAAP Financial Measures Beta Bionics, Inc. (the “Company”) prepares and presents the Company’s financial statements in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). The Company believes adjusted EBITDA as a non-GAAP measure is useful in evaluating the Company’s operating performance and uses adjusted EBITDA to evaluate ongoing operations and for internal planning and forecasting purposes. The Company believes that this non-GAAP financial measure, when taken together with the corresponding GAAP financial measures, provide meaningful supplemental information regarding the Company’s performance by excluding certain items that may not be indicative of the Company’s business, results of operations, or outlook. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in the Company’s industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of the Company’s non-GAAP financial measures as tools for comparison. A reconciliation is provided below for adjusted EBITDA to the most directly comparable financial measure stated in accordance with GAAP in Table E below. The Company calculates adjusted EBITDA as net loss adjusted to exclude (i) depreciation and amortization expense, (ii) stock-based compensation expense, (iii) interest income, (iv) provision for state taxes and (v) change in fair value of warrant liabilities. Some of the limitations of adjusted EBITDA include: (i) adjusted EBITDA does not properly reflect capital commitments to be paid in the future and (ii) although depreciation and amortization expense are non-cash charges, the underlying assets may need to be replaced and adjusted EBITDA does not reflect these capital expenditures. The Company’s adjusted EBITDA may not be comparable to similarly titled measures of other companies because they may not calculate adjusted EBITDA in the same manner as the Company calculates the measure, limiting its usefulness as a comparative measure. In evaluating adjusted EBITDA, you should be aware that in the future the Company will incur expenses similar to the adjustments in this presentation. The Company’s presentation of adjusted EBITDA should not be construed as an inference that the Company’s future results will be unaffected by these expenses or any unusual or non-recurring items. When evaluating the Company’s performance, you should consider adjusted EBITDA alongside other financial performance measures, including the Company’s net loss and other GAAP results. Investors are encouraged to review the related GAAP financial measures and the reconciliation of this non-GAAP financial measure to its most directly comparable GAAP financial measure, and not to rely on any single financial measure to evaluate the Company’s business. This non-GAAP measure has limitations as an analytical tool and should not be construed as an inference that the Company’s future results will be unaffected by unusual or non-recurring items. Therefore, this non-GAAP financial measure should be considered in addition to, not as a substitute for, or in isolation from, measures prepared in accordance with GAAP. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Beta Bionics, Inc. (the “Company”) regarding our regulatory development plans for the iLet and other product candidates; the markets and market opportunities for the iLet and other product candidates, if approved; the timing, likelihood or success of our business strategy, including commercialization and our multi-channel reimbursement strategy, as well as plans and objectives of management for future operations; our anticipated growth and other measures of future operating results and financial performance, including 2025 full year guidance regarding revenue, new patient starts through the PBP channel and gross margin; and the potential benefits of the addition of the iLet to Prime Therapeutics’ national commercial formulary. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, including, without limitation, risks inherent in developing product candidates, future results from the Company’s ongoing and future studies and clinical trials, the Company’s ability to obtain adequate financing to fund its product development and other expenses, risks that real-world data or future results may not be consistent with interim, initial or preliminary results or results from prior preclinical studies or clinical trials, trends in the industry, the Company’s relationships with its existing and future collaboration partners, the legal and regulatory framework for the industry, future expenditures and the potential impacts of global macroeconomic conditions. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission, including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Beta Bionics, Inc.Statements of Operations and Comprehensive Loss (unaudited)Table A       Three Months Ended March 31,(In thousands, except number of shares and per share data) 2025   2024 Net sales$17,639  $12,933 Cost of sales 8,668   5,732 Gross profit 8,971   7,201 Gross margin 50.9%  55.7%Operating expenses:     Research and development 7,590   5,479 Sales and marketing 13,402   7,663 General and administrative 6,621   3,512 Total operating expenses 27,613   16,654 Loss from operations (18,642)  (9,453)Other income (expense):     Interest income 2,436   1,139 Other income —   4 Change in fair value of warrant liabilities (12,450)  (4,139)Total other expense, net (10,014)  (2,996)Net loss$(28,656) $(12,449)Other comprehensive income (loss):     Unrealized gain (loss) on short-term investments 175   (132)Comprehensive loss$(28,481) $(12,581)Net loss per share attributable to common stockholders,basic and diluted$(0.93) $(2.07)Weighted-average common shares outstanding, basic anddiluted30,714,769   6,021,882             Beta Bionics, Inc.Balance Sheets (unaudited)Table B      (In thousands, except number of shares)March 31, December 31, 2025   2024 Assets     Current assets:     Cash and cash equivalents$42,454  $30,432 Short-term investments 189,019   73,143 Accounts receivable, net 9,060   11,996 Inventories, net 15,730   13,320 Prepaid expenses and other current assets 5,652   4,032 Total current assets 261,915   132,923 Property and equipment, net 5,515   4,776 Operating lease right-of-use asset 6,344   6,645 Restricted cash 100   100 Deferred offering costs —   5,051 Long-term investments 64,004   — Other long-term assets 146   150 Total assets$338,024  $149,645       Liabilities, Convertible Preferred Stock and Stockholders’ Equity (Deficit)     Current liabilities:     Accounts payable$3,454  $2,852 Accrued expenses and other current liabilities 10,565   15,828 Operating lease liabilities 1,524   1,529 Deferred revenue 949   939 Total current liabilities 16,492   21,148 Operating lease liabilities, net of current portion 5,450   5,726 Deferred revenue, net of current portion 2,330   1,860 Warrant liabilities —   44,898 Total liabilities 24,272   73,632 Commitments and contingencies     Convertible preferred stock (Series A, A-2, B, B-2, C, D and E), par value of $0.0001 per share; no and 34,966,547 shares authorized at March 31, 2025 and December 31, 2024, respectively; no and 17,228,954 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively; liquidation preference of no and $355,162 at March 31, 2025 and December 31, 2024, respectively —   321,373 Stockholders’ equity (deficit):     Class A common stock, par value of $0.0001 per share; no and 5,790,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; no and 2,939,085 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively —   1 Class B common stock, par value of $0.0001 per share; no and 70,000,000 shares authorized at March 31, 2025 and December 31, 2024, respectively; no and 3,679,790 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively —   — Class C common stock, par value of $0.0001 per share; no and 96,910 shares authorized at March 31, 2025 and December 31, 2024, respectively; no and 48,918 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively —   — Preferred stock, par value of $0.0001 per share; 10,000,000 and no shares authorized at March 31, 2025 and December 31, 2024, respectively; no shares issued or outstanding at March 31, 2025 and December 31, 2024 —   — Common stock, par value of $0.0001 per share; 700,000,000 and no shares authorized at March 31, 2025 and December 31, 2024, respectively; 43,353,890 and no shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 4   — Additional paid-in capital 638,901   51,311 Accumulated other comprehensive income 240   65 Accumulated deficit (325,393)  (296,737)Total stockholders’ equity (deficit) 313,752   (245,360)Total liabilities, convertible preferred stock and stockholders’ deficit$338,024  $149,645             Beta Bionics, Inc.Net Sales by Channel (unaudited)Table C      (In thousands)Three Months Ended March 31, 2025   2024 DME channel:     iLet(1)$9,628  $10,373 Single-use products 4,199   1,732 Total DME channel 13,827   12,105       PBP channel:     iLet(1) 506   291 Single-use products 3,306   537 Total PBP channel 3,812   828 Total net sales$17,639  $12,933 (1)iLet includes the over-time recognition software updates and mobile app access.            Beta Bionics, Inc.Key Business Metrics (unaudited)Table D       Three Months Ended March 31, 2025   2024 New patient starts(1) 3,853   2,597 New patient starts from MDI as a percentage of total new patient starts 71%  66%Installed customer base(2) 19,151   4,901 (1)In the month ended March 31, 2024 a mid-single digit percentage of our new patient starts were reimbursed through the PBP channel. In the month ended March 31, 2025 a low 20s percentage of our new patient starts were reimbursed through the PBP channel.(2)The installed customer base represents all new patient starts, over a rolling four-year period basis. This period reflects our in-warranty customer base under the typical four-year reimbursement cycle and helps us understand the total number of patients using the iLet.            Beta Bionics, Inc.Reconciliation of GAAP versus Non-GAAP Financial Results (unaudited)Table E      (In thousands)Three Months Ended March 31, 2025   2024 Net loss$(28,656) $(12,449)Add:     Depreciation expense 303   287 Stock-based compensation expense 2,804   1,357 Interest income (2,436)  (1,139)Provision for state taxes —   — Change in fair value of warrant liabilities 12,450   4,139 Adjusted EBITDA$(15,535) $(7,805) Investor Relations:Blake BeberHead of Investor Relationsir@betabionics.com Media and Public Relations: Karen HynesVice President of Marketingmedia@betabionics.com Source: Beta Bionics, Inc.

Related News